Synlogic Inc (SYBX) Given Average Recommendation of “Buy” by Brokerages

Synlogic Inc (NASDAQ:SYBX) has received an average rating of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $18.47.

SYBX has been the topic of a number of recent analyst reports. BTIG Research initiated coverage on shares of Synlogic in a research note on Tuesday, February 12th. They issued a “buy” rating and a $22.00 price objective on the stock. Chardan Capital initiated coverage on shares of Synlogic in a research note on Thursday, December 13th. They issued a “buy” rating and a $20.00 price objective on the stock. ValuEngine raised shares of Synlogic from a “hold” rating to a “buy” rating in a research note on Tuesday, December 11th. HC Wainwright set a $20.00 price objective on shares of Synlogic and gave the company a “buy” rating in a research note on Monday, December 10th. Finally, Zacks Investment Research raised shares of Synlogic from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a research note on Friday, March 15th.

Shares of NASDAQ:SYBX opened at $7.59 on Friday. The company has a market capitalization of $191.77 million, a P/E ratio of -3.74 and a beta of 2.38. Synlogic has a 1 year low of $5.75 and a 1 year high of $14.59.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.24 million. Synlogic had a negative net margin of 1,922.02% and a negative return on equity of 36.38%. On average, equities analysts anticipate that Synlogic will post -2.19 EPS for the current fiscal year.

In other Synlogic news, insider Paul Francis Miller sold 9,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 13th. The shares were sold at an average price of $9.75, for a total value of $87,750.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 23.30% of the company’s stock.

Several large investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in shares of Synlogic by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 155,161 shares of the biotechnology company’s stock worth $1,087,000 after purchasing an additional 16,591 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Synlogic by 50.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 316,656 shares of the biotechnology company’s stock worth $2,220,000 after purchasing an additional 105,628 shares during the period. Northern Trust Corp lifted its holdings in shares of Synlogic by 1.2% during the fourth quarter. Northern Trust Corp now owns 167,135 shares of the biotechnology company’s stock worth $1,172,000 after purchasing an additional 2,005 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Synlogic by 12.1% during the fourth quarter. Bank of New York Mellon Corp now owns 56,774 shares of the biotechnology company’s stock worth $398,000 after purchasing an additional 6,129 shares during the period. Finally, BlackRock Inc. lifted its holdings in shares of Synlogic by 33.4% during the fourth quarter. BlackRock Inc. now owns 1,248,355 shares of the biotechnology company’s stock worth $8,750,000 after purchasing an additional 312,398 shares during the period. Institutional investors own 81.05% of the company’s stock.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Read More: How Do You Calculate Return on Investment (ROI)?

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.